Checkpoint Inhibitor Pneumonitis
Conditions
Interventions
Exposure group:None
Control group:None
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: a) Age = 18 years; b) Scheduled to receive anti-tumor therapy with ICIs (specific drugs include CTLA-4 monoclonal antibodies such as ipilimumab; PD-1 monoclonal antibodies such as nivolumab, pembrolizumab, sintilimab, camrelizumab, and tislelizumab; as well as marketed PD-L1 monoclonal antibodies such as durvalumab and atezolizumab); c) Patients provide informed consent and are willing to provide clinical routine diagnosis and treatment data for analysis in this study. Depending on their personal preference, patients may choose whether to undergo regular assessments using the intelligent evaluation system for checkpoint inhibitor pneumonitis.
Exclusion criteria
Exclusion criteria: a) The patient is currently participating in an interventional clinical study; b) The patient has not been treated or followed up at the aforementioned research center.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of CIP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of CIP diagnosis;Time to diagnosis of CIP;Hospitalization duration for CIP treatment;Total course cost for CIP treatment; | — |
Countries
China
Contacts
Public ContactZhou Jianya
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed